Tumor suppressor genes

Cell

Volumn 64, Issue 2, 1991, Pages 313-326

  Marshall, Christopher J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOMATOUS POLYP; CANCER INHIBITION; HUMAN; NEPHROBLASTOMA; NEUROFIBROMATOSIS; PRIORITY JOURNAL; RETINOBLASTOMA; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMAL; CELL TRANSFORMATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HETEROZYGOTE; HUMAN; HYBRID CELLS; MODELS, GENETIC; NEOPLASMS;

EID: 0026059515     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/0092-8674(91)90641-B     Document Type: Review

References (152)

1. High frequency of APC loss in soradic colorectal carcinoma due to breaks clustered in 5q21-22
2. Chromosome 17 deletion and p53 gene mutations in colorectal carcinomas
3. Suppression of human colorectal carcinoma cell growth by wild-type p53
4. Abnormalities of chromosomes 13 in retinoblastomas from individuals with normal constitutional karyotypes
5. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins
6. ras genes
7. Gene for von Recklinghausen neurofibromatosis is in the pericentromeric region of chromosome 17
8. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines
9. Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2
10. Localisation of the gene for familial adenomatous polyposis on chromosome 5
11. Genetic analysis of colorectal cancer
12. Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma
13. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene
14. Mouse p53 inhibits SV40 origin-dependent DNA replication
15. Abnormal structure and expression of p53 gene in human hepatocellular carcinoma
16. Sequence homology shared by neurofibromatosis type-1 gene and IRA-1 and IRA-2 negative regulators of the RAS cyclic AMP pathway
17. The retinoblastoma protein is phosphorylated during specific phases of the cell cycle
18. Mutation selection and the natural history of cancer
19. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilm's tumor locus
20. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma
21. Genetic origin of mutations predisposing to retinoblastoma
22. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations
23. Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation
24. SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene
25. p53 functions as a cell cycle control protein in osteosarcomas
26. ras upon T-cell activation
27. Parental origin of mutations of the retinoblastoma gene
28. Participation of p53 cellular tumour antigen in transformation of normal embryonic cells
29. Meth A fibrosarcoma cells express two transforming mutant p53 species
30. Wild-type p53 can inhibit oncogene-mediated focus formation
31. A genetic model for colorectal tumorigenesis
32. Clonal analysis of human colorectal tumors
33. Identification of a chromosome 18q gene that is altered in colorectal cancers
34. Presence of a potent transcription activating sequence in the p53 protein
35. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life
36. The p53 protooncogene can act as a suppressor of transformation
37. Retinoblastoma and chromosome 13
38. Aniridia-Wilms' tumor association: evidence for specific deletion of 11p13
39. Inhibition of GTPase activating protein stimulation of Ras-p21 GTPase by the Krev-1 gene products
40. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma
41. Expression and state of phosphorylation of the retinoblastoma susceptibility gene product in cycling and nonocycling human hematopoietic cells
42. The E7 proteins of the nononcogenic human papillomavirus type 6b (HPV-6B) and of the oncogenic HPV-16 differ in retinoblastoma protein binding and other properties
43. p53 and DNA polymerase α compete for binding to SV40 T antigen
44. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form
45. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping
46. Multipoint linkage analysis of neurofibromatosis type I: an international colaboration
47. When the products of oncogenes and anti-oncogenes meet
48. Familial predisposition to Wilms' tumour does not map to the short arm of chromosome 11
49. An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilm's tumor
50. Different tumor-derived p53 mutants exhibit distinct biological activities
51. ras and GAP—who's controlling whom?
52. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC
53. The analysis of malignancy by cell fusion: the position in 1988
54. c-myc antisense oligodeoxy-nucleotide inhibits entry into S phase but not progress from G0 to G1
55. Tumor-specific loss of 11p15.5 alleles in del11p13 Wilm's tumor and in familial adrenocortical carcinoma
56. Point mutational inactivation of the retinoblastoma antioncogene
57. Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells
58. Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells
59. Lack of linkage of familial Wilm's tumour to chromosomal band 11p13
60. Cooperation between oncogenes
61. Increased expression of mutant forms of p53 oncogene in primary lung cancer
62. Paternal origin of new mutations in von Recklinghausen neurofibromatosis
63. Mitotic recombination of chromosome 17 in astrocytomas
64. Cellular immortalisation by a cDNA encoding the transformation-association phosphoprotein p53
65. A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding
66. A ras-related gene with transformation suppressor activity
67. Mutation and cancer: statistical study of retinoblastoma
68. Familial Wiedemann-Beckwith syndrome and a second Wilms tumor locus both map to 11p15
69. Growth inhibition by TGF-β linked to suppression of retinoblastoma protein phosphorylation
70. T-antigen is bound to host protein in SV40-transformed cells
71. Inactivation of the retinoblastoma susceptibility gene in human breast cancers
72. Human retinoblastoma susceptibility gene: cloning, identification, and sequences
73. The gene for familial polyposis coli maps to the long arm of chromosome 5
74. Tumor metastasis and angiogenesis: an imbalance of positive and negative regulation
75. SV40 large T antigen binds preferentially to an underphosphorylated member of the retinoblastoma susceptibility gene product family
76. The retinoblastoma susceptibility gene product undergoes cell cycle-dependent dephosphorylation and binding to and release from SV40 large T
77. Two G protein oncogenes in human endocrine tumors
78. Allele loss on short arm of chromosome 18 in breast cancers
79. Binding of p53 and p105-RB is not sufficient for oncogenic transformation by a hybrid polyomavirus-simian virus 40 large T antigen
80. Role of differentiation induction in tumor suppression
81. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21
82. Deletion of genes on chromosome 1 in endocrine neoplasia
83. Genetics of Wilm's tumor
84. The p53 tumor suppressor protein is phosphorylated at serine 389 by casein kinase II
85. Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis
86. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53
87. Cell cycle-dependent regulation of phosphorylation of the human retinoblastoma gene product
88. TGF-β stimulation and inhibition of cell proliferation: new mechanistic insights
89. Rearrangement of the cellular p53 gene in erythrleukemic cells transformed by Friend virus
90. Mechanisms of p53 loss in human sarcomas
91. Complex formation of human papilomavirus E7 proteins with the retinoblastoma tumor suppressor gene product
92. Mutations in the p53 gene occur in diverse human tumour types
93. Antisense RNA of proto-oncogene c-fos blocks renewed growth of quiescent 3T3 cells
94. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation
95. Are different events involved in the development of sporadic versus hereditary tumours? The possible importance of the microenvironment in hereditary cancer
96. The role of differentiation in the suppression of tumorigenicity in human hybrids
97. Automatic microinjection system facilitates detection of growth inhibitory mRNA
98. Evidence for the recessive nature of cellular immortality
99. Genetic analysis of indefinite division in human cells: identification of four complementation groups
100. Transforminng growth factor beta 1 suppression of c-myc gene transcription: role in inhibition of keratinocyte proliferation
101. TGF-β1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains
102. Genetics and biochemistry of collagen binding-triggerred glandular differentiation in a human colon carcinoma cell line
103. Gene losses in human tumours
104. Derivation of mouse intestinal crypts from single progenitor cells
105. The candidate Wilm's tumour gene is involved in genitourinary development
106. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene
107. Loss of allelic heterozygosity at a second locus on chromosome 11 in sporadic Wilm's tumor cells
108. The anridia-Wilms' tumor association: the critical role of chromosome band 11p13
109. Negative regulation of human c-fos expression by the retinoblastoma gene product
110. p53 mutations in colorectal cancer
111. Complete map of the WAGR region of 11p13 localizes a candidate Wilms' tumor gene
112. Reduced Nm23/Awd protein in tumour metastasis and aberrant Drosophila development
113. Genetic suppression of tumor formation
114. Genome imprinting, cellular mosaicism and carcinogenesis
115. Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells
116. Loss of consitutional heterozygosity in colorectal tumors from patients with familial polyposis coli and those with nonpolyposis colorectal carcinoma
117. Introduction of human chromosome 11 via microcell transfer controls tumorigenic expression of HeLa cells
118. Partial reversion of the transformed phenotype in HRAS-transfected tumorigenic cells by transfer of a human gene
119. Genes specifically expressed at growth arrest of mammalian cells
120. c-src at the sites phosphorylated during fibroblast mitosis
121. Introduction of normal chromsome 3p modulates the tumorigenicity of a human renal cell carcinoma cell line YCR
122. Chromosome 5 allele loss in human colorectal carcinomas
123. Suppression of malignancy in human cells
124. Genetic analysis of human malignancy using somatic cell hybrids and monochrosomes transfer
125. Growth-regulatory control of human cell hybrids in nude mice
126. Failure to phosphorylate the retinoblastoma gene product in senescent human fibroblasts
127. Identification of a single chromosome in the normal human genome essential for suppression of hamster cell transformation
128. Induction of cellular senescence in immortalized cells by human chromosome 1
129. p53: a frequent target for genetic abnormalities in lung cancer
130. Structural rearrangement of the retinoblastoma gene in human breast carcinoma
131. Nonfunctional mutants of the retinoblastoma protein are characterized by defects in phosphorylation viral oncoprotein association and nuclear tethering
132. Preferential mutation of paternally derived RB gene as the initial event in sporadic osteosarcoma
133. Molecular cloning of two types of GAP complementary DNA from human placenta
134. Tumorigenicity in human melanoma cell lines controlled by introduction of human chromosome 6
135. Role for the Wilms tumor gene in genital development?
136. CpG island clones from a deletion encompassing the gene for adenomatous polyposis coli
137. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus
138. Genetic alterations during colorectal-tumor development
139. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients
140. The murine p53 protein blocks replication of SV40 in vitro by inhibiting the initiation functions of SV40 large T antigen
141. Complementation of the tumorigenic phenotype in human cell hybrids
142. Association of human papillomavirus types 16 and 18 E6 proteins with p53
143. Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product
144. GAPs in understanding Ras
145. Reconstitution of p53 expression in a nonproducer Ab-MulV-transformed cell line by transfection of a functional p53 gene
146. The neurofibromatosis type 1 gene encodes a protein related to GAP
147. The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae
148. + channels
149. Loss of heterozygosity on chromosomes 3, 13 and 17 in small-cell carcinoma and on chromosome 3 in adenocarcinoma of the lung
150. Suppression of c-ras transformation by GTPase-activating protein
151. Preferential germlline mutation of the paternal allele in retinoblastoma